This study investigated the regulation of PD-L1 expression by calcium signaling in oral squamous cell carcinoma (OSCC). We found that IFN-γ stimulation markedly altered the intracellular proteome and activated calcium-associated pathways. Pharmacological inhibition of store-operated calcium entry (SOCE) using the Orai1 inhibitor Synta66 suppressed IFN-γ-induced PD-L1 expression in a dose-dependent manner. Consistently, knockdown of Orai1 or STIM1 attenuated PD-L1 induction under IFN-γ stimulation, while basal expression remained unchanged. Inhibition of CaMK2 and CaMKK2 also reduced PD-L1 expression, indicating involvement of calmodulin-dependent kinase pathways. Functionally, Orai1 or STIM1 knockdown enhanced CD8⁺ T cell-mediated suppression of OSCC cell proliferation. Collectively, these results demonstrate that SOCE-mediated calcium signaling and downstream kinases regulate IFN-γ-induced PD-L1 expression and suggest that targeting SOCE components could represent a novel therapeutic approach to overcoming tumor immune evasion in OSCC. (132 words).
1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
Introduction: We previously identified a novel magnetic organic compound, N,N'-bis(salicylidene)ethylenediamine iron [Fe(Salen)], as an anti-cancer agent with intrinsic magnetism. Fe(Salen) can generate heat, i.e. hyperthermia upon exposure to alternating magnetic field (AMF) like an induction cooker. The purpose of the study was to evaluate the antitumor effect of intra-arterial (i.a.) selective injection of Fe(Salen) by catheter with/without the AMF-induced hyperthermia or intra-venous (i.v.) injection. We also investigated the anticancer mechanism of Fe(Salen) and the therapeutic dose through toxicity study. Methods: Rabbit squamous cell carcinoma (VX2) cells were purchased from ATCC. Rabbit tumor model implanted with VX2 cells in the right femur was used. Western blotting, mitochondrial membrane potential and Immunocytochemistry for STAT3 subcellular distribution were performed. Results: Intra-arterial selective injection of Fe(Salen) by catheter showed the greater antitumor effect than that of i.v. injection. The combination of intra-arterial injection of Fe(Salen) and AMF exposure showed the greater effect than either Fe(Salen) or methotrexate (MTX) without AMF. Fe(Salen) showed antitumor effect via MEK/ERK/STAT3 signaling pathways. Conclusion: This is the first report that the effectiveness of Fe(Salen) was evaluated in the point of administration route. These results indicate the effective arterial injection of Fe(Salen) by catheter and the development of new strategy of simultaneous hyperthermia-chemotherapy.
1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
【Background】The EP4 prostanoid receptors are one of the four receptor subtypes for Prostaglandin E2 (PGE2). EP4 plays an important role in cancer progression. Its inhibition is a potential strategy for cancer therapy. However, little information is available regarding cell apoptosis and cellular signaling pathway of EP4 in oral cancer. In current study, we examined that EP4 signal regulates cell apoptosis and chemotherapeutic resistance in oral cancer.【Material and Method】Human-derived tongue squamous cell carcinoma cell lines, HSC-3 was used. Western blot analysis was performed to evaluate the proteins, which is associated with cell migration and apoptosis in cancer (E-cadherin, N-cadherin, claudin-1, ZEB1, ZO-1, galectin-3, fibronectin, Bcl-2, Bax). Cell apoptosis was evaluated by flowcytometry. 【Result】EP4 agonist (ONO-AE1-437) increased expression of galectin-3 in HSC-3 cells (p<0.001). EP4 agonist also increased claudin-1 expression. The other proteins were not changed by the EP4 agonist stimulation. Furthermore, EP4 agonist inhibited cisplatin-induced early apoptosis of oral cancer cells and decreased late apoptosis and necrosis.【Conclusion】Activation of EP4 signal may increase the expression of galectin-3 and promote cell apoptosis, resulting in a chemotherapeutic resistance of oral cancer.
20 May 2021 in Japanese Journal of Oral and Maxillofacial Surgery
Sialolithiasis is rare in children. We thus examined the 111 cases of sialolithiasis patients younger than 16 years old who were treated in the Department of Oral and Maxillofacial Surgery / Orthodontics, Yokohama City University Hospital between January 2007 and August 2018. The patients included 61 males and 50 females. Their ages ranged from 4 to 15 years. 110 patients had sialoliths in the submandibular gland and one patient in the parotid gland. Of the 111 patients, 78 complained of swelling on their first visit. There was one patient with no symptoms. Almost all patients (109) underwent a CT scan and two patients underwent occlusal radiography. The majority of the patients (84) had only one sialolith, and most of the sialolith were less than 5 mm in diameter. The submandibular sialoliths were frequently seen in the transitional region and the gland duct. Of the 111 patients, 60 underwent intraoral removal, 33 underwent endoscopic removal with sialendoscope, and 9 underwent removal using both approaches. This study clarified the characteristics and treatment of pediatric sialolithiasis patients.